# Tangningtongluo Tablet for People With Prediabetes

Study · id `cardio:ct-nct05126251` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05126251](<https://clinicaltrials.gov/study/NCT05126251>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05126251

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT05126251. Randomized; triple masking; primary purpose treatment. Start 2021-12-13 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT05126251, source copy `cardio:ctgov-nct05126251-2022-03-22`, retrieved 2026-11-18)
- Started: 2021-12-13 (actual) (ClinicalTrials.gov record NCT05126251, source copy `cardio:ctgov-nct05126251-2022-03-22`, retrieved 2026-11-18)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT05126251, source copy `cardio:ctgov-nct05126251-2022-03-22`, retrieved 2026-11-18)
- Completion: 2023-06-30 (anticipated) (ClinicalTrials.gov record NCT05126251, source copy `cardio:ctgov-nct05126251-2022-03-22`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT05126251, source copy `cardio:ctgov-nct05126251-2022-03-22`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05126251-2022-03-22`, retrieved 2026-11-18)

## The registry's words

- Brief title: Tangningtongluo Tablet for People With Prediabetes
- Condition: Prediabetes
- Intervention (Drug): Tangningtongluo tablet
- Intervention (Behavioral): lifestyle intervention
- Lead sponsor: Beijing University of Chinese Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry lists this organization as the lead sponsor: Beijing University of Chinese Medicine (`cardio:org-beijing-university-of-chinese-medicine`)

## Provenance

Content hash: 36f317e96e798934459b5c54c254c39bb3bba56fa6433db6e441fd38f179f024
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
